Semax – Learning Health

What it is

Semax is a seven-residue synthetic peptide built on a fragment of adrenocorticotropic hormone. The first four residues correspond to ACTH(4-7) — the stretch associated with ACTH’s effects on learning and memory rather than its hormonal action on the adrenal gland. The last three, Pro-Gly-Pro, were added as a stabilising tail: that motif resists peptidases, extending what would otherwise be a half-life measured in seconds.

It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences and has been registered as a medicine in Russia since the 1990s, used for ischaemic stroke, transient ischaemic attack, cognitive disorders and optic nerve disease. It is usually given intranasally, which is a deliberate choice — the nasal route offers partial access to the brain for peptides that would not otherwise cross the blood-brain barrier.

Critically, this creates an asymmetry that runs through everything below: Semax is a normal prescription medicine in one country and an unapproved research chemical everywhere else, and the evidence base has essentially never crossed that border.

What it does in the body

The mechanistic work is the most reproducible part of the Semax literature, and it points at neurotrophins. A single application of 50 µg/kg in rats produced a maximal 1.4-fold increase in BDNF protein, a 1.6-fold increase in trkB tyrosine phosphorylation, and three-fold and two-fold increases in exon III BDNF and trkB messenger RNA respectively in the hippocampus. The same animals showed a distinct increase in conditioned avoidance reactions. BDNF and its receptor trkB are central to synaptic plasticity, which gives the cognitive claims a coherent mechanism.

A genome-wide transcriptional analysis in a rat model of focal cerebral ischaemia found Semax affected the expression of genes related to the immune and vascular systems — consistent with a broad modulatory effect on the post-stroke environment rather than a single receptor action.

What the human evidence shows

There are human studies. Their design is the problem.

Acute stroke, 1997. Thirty patients in the acute period of hemispheric ischaemic stroke received Semax in combined intensive therapy. The comparison group was 80 patients with strokes of analogous severity and location treated by conventional therapy — a non-randomised, non-blinded control. The authors reported faster regression of general cerebral and focal, especially motor, disorders, and identified effective daily doses by stroke severity.
Stroke rehabilitation, 2018. One hundred and ten patients after ischaemic stroke were divided into early (89±9 days) and late (214±22 days) rehabilitation groups, each subdivided by whether they received Semax. Plasma BDNF rose and stayed high with Semax; Barthel index recovery was faster and better, with less effect on paresis. There was no placebo arm — the comparison was with patients not given the drug.
Optic nerve disease, 2000. A controlled clinical trial of what the title calls a “new Russian drug” in optic nerve disease.

What "no placebo arm" costs you here

Stroke recovery is a moving target: spontaneous neurological improvement over the first months is substantial and highly variable, and rehabilitation intensity differs between patients. Comparing treated patients with untreated patients who were not randomly assigned cannot separate the drug from differences in who got it and what else they received. The BDNF rise is a genuine biological measurement; the functional outcome claim is not established by this design.

No multi-centre randomised placebo-controlled trial of Semax has been published, and no trial has been conducted outside Russia.

Claims and what backs them

Claim as usually stated	Verdict	What the published evidence actually shows
Increases BDNF	Supported	Shown in rat hippocampus with matched increases in trkB expression and phosphorylation, and plasma BDNF rose in the 2018 human rehabilitation study.
Improves recovery after ischaemic stroke	Mixed	Positive in Russian clinical studies spanning 1997 to 2018, in which the comparison groups were not randomised and no placebo was used. It is a registered indication in Russia.
Enhances cognition in healthy people	Unproven	No trial has tested Semax in healthy adults for cognitive enhancement, which is how it is predominantly marketed online.
Neuroprotective	Mixed	Consistent in rat ischaemia models including genome-wide expression work. Translation to human neuroprotection is not demonstrated by controlled trials.
A safe, well-studied nootropic	Unproven	When a European medicines control laboratory analysed seized preparations containing Semax, it noted the peptide had not completed any clinical trials to its knowledge. Decades of Russian clinical use is a real observation, but is not a safety database by Western standards.

Risks and unknowns

An ACTH-derived peptide with an uncertain hormonal boundary. The ACTH(4-7) fragment was chosen for behavioural rather than endocrine effects, and Semax is not reported to stimulate cortisol release. But it is derived from a stress-axis hormone, and hypothalamic-pituitary-adrenal effects of long-term use in healthy people have not been characterised.

The grey market is documented, not hypothetical. At the end of 2017 and again in 2018, two unknown suspicious preparations submitted to a Belgian official medicines control laboratory turned out to contain Selank and Semax. The authors noted these nootropic research peptides were freely available online as lyophilised powder for injection or in nasal sprays, and used the finding as a prompt to develop screening methods — because control laboratories needed to anticipate what they called potentially dangerous molecules.

Single-country, single-tradition evidence. Almost all clinical work comes from a small number of Russian groups connected to the institute that developed the compound. That is not an accusation of bad faith; it is a statement about the absence of independent replication, which is how science corrects itself.

Nothing is known about chronic use in healthy adults. The registered indications are acute and sub-acute neurological conditions treated in courses of days to weeks. Indefinite use for focus is outside anything studied.

Where regulators stand

RussiaRegistered as a medicine, used for ischaemic stroke, transient ischaemic attack, cognitive and memory disorders and optic nerve disease. This is a genuine national approval, granted on a national evidence base.

United StatesNot approved for any use. “Semax (heptapeptide)” appears in the FDA’s table of bulk drug substances previously in Category 2 whose nominations were withdrawn by the nominators.

The July 2026 voteOn 23–24 July 2026 the FDA’s Pharmacy Compounding Advisory Committee reviewed seven peptides for the 503A bulks list, against the unanimous recommendation of the agency’s own scientific staff, who noted there was no human clinical data for four of the seven. Semax was cleared by the committee on 24 July 2026 by a narrow margin. The vote is advisory, changes nothing legally, and no final rule has been published.

European UnionNo marketing authorisation. Preparations containing Semax have been seized and analysed by official medicines control laboratories as illegal products.

SportNot named on the WADA 2026 Prohibited List. As a substance without approval for human therapeutic use in the relevant jurisdictions, the S0 catch-all would apply.

The bottom line

Semax occupies an unusual position: a real registered medicine with thirty years of clinical use in one country, and effectively zero standing anywhere else. The mechanistic story — raising BDNF and trkB signalling — is reproducible and sensible, and the stroke studies are not fabricated.

But they were not randomised, not placebo-controlled, and never replicated outside Russia, which means the central question of whether the functional improvements belong to the drug has not been answered. And the modern use case — a healthy person using a nasal spray for focus — has not been studied at all, in any country, by anyone.

References

Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. 2006;1117(1):54–60 PMID 16996037
Medvedeva EV, Dmitrieva VG, Povarova OV, et al. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics. 2014;15:228 PMID 24661604
Gusev EI, Skvortsova VI, Miasoedov NF, et al. Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study). Zh Nevrol Psikhiatr Im S S Korsakova. 1997;97(6):26–34 PMID 11517472 — in Russian; non-randomised control group
Gusev EI, Martynov MY, Kostenko EV, Petrova LV, Bobyreva SN. The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(3):61–68 PMID 29798983 — in Russian; no placebo arm
Polunin GS, Nurieva SM, Baiandin DL, et al. Evaluation of therapeutic effect of new Russian drug semax in optic nerve disease. Vestn Oftalmol. 2000;116(1):15–18 PMID 10741256 — in Russian
Vanhee C, Francotte A, Janvier S, Deconinck E. The occurrence of putative cognitive enhancing research peptides in seized pharmaceutical preparations. Drug Test Anal. 2020;12(3):371–381 PMID 31667971